Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Oxford Bioscience Partners
AddedFeb 13, 2024
UpdatedJul 16, 2026
Oxford Bioscience Partners

Oxford Bioscience Partners

Operating

Oxford Bioscience Partners: A global venture capital firm investing in life sciences, tech, energy, and healthcare.

Location
Boston, MA, US
Founded
1992
Firm
Compare
Portfolio
Employees
Website

Investments

Yolia Health
Yolia Health

Total Raised

$5M

Rounds

4

Series A$3MJanuary 2017
CardioFocus
CardioFocus
Public

Total Raised

$268M

Rounds

20

Debt Financing$2.4MMay 2014
Series C$30.6MFebruary 2011
Glori Energy
Glori Energy
Acquired

Total Raised

$43M

Rounds

6

Series C$20MJanuary 2012
Adastra Pharmaceuticals
Adastra Pharmaceuticals
Acquired

Total Raised

$85M

Rounds

10

Series Unknown$5MApril 2010
Series A$40MMarch 2007
Molecular Biometrics
Molecular Biometrics

Total Raised

$24.5M

Rounds

2

Series B$12.5MJanuary 2010
Series A$12MNovember 2008
Cambrios Technologies
Cambrios Technologies

Total Raised

$81.1M

Rounds

9

Series D$14.5MNovember 2009
Series C$18.5MApril 2007
Series B$12MFebruary 2005
Elixir Pharmaceuticals
Elixir Pharmaceuticals
Public

Total Raised

$98.5M

Rounds

4

Series D$12MMay 2009
Series C$31MNovember 2006
Zettacore
Zettacore

Total Raised

$56M

Rounds

4

Series C$15MMay 2008
BrainCells
BrainCells

Total Raised

$73.7M

Rounds

5

Series B$30MMarch 2008
Series A$17.7MJuly 2005
Select Laboratory Partners
Select Laboratory Partners

Total Raised

$57M

Rounds

5

Series D$16MJanuary 2008
Hydrocision
Hydrocision

Total Raised

$33.8M

Rounds

8

Series H$4.8MJanuary 2008
Series G$12.7MJanuary 2007
Ensemble Discovery
Ensemble Discovery

Total Raised

$30M

Rounds

2

Series B$15MNovember 2007
Courtagen Life Sciences
Courtagen Life Sciences
Acquired

Total Raised

$65M

Rounds

9

Series A$9.5MNovember 2007
Series Unknown$7.6MFebruary 2006
Series Unknown$6.6MSeptember 2004
Xencor
Xencor
Public

Total Raised

$133.4M

Rounds

9

Series E$15MOctober 2007
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Public

Total Raised

$84.6M

Rounds

9

Series Unknown$20MAugust 2004